摘要
中医药作为我国的传统医药产业,拥有不可替代的重要地位和独特作用。通过对中医药产业政策的分级评估,旨在深入挖掘政策核心内容与薄弱部分,在对政策评价分析的同时,提出合理建议,以期为今后中医药产业的发展提供更多的创新思路。本文基于文本挖掘与统计分析方法、通过构建PMC模型对2016〜2021年4月我国具有代表性的19项中医药产业政策内容进行量化评价。19项政策组合中有16项政策为优秀型政策,3项为良好型政策。通过政策P16与P2对比,P16着眼行业全局;P2更侧重中药物流基地的建设发展,具有领域针对性。建议良好型政策细化财政扶持、人才培养机制等措施,进一步加强政策保障力度。
As a traditional medicine industry in China,Chinese medicine has an irreplaceable important position and unique role. Through the graded evaluation of Chinese medicine industry policies,the core content and weak parts were explored. Based on which,reasonable suggestions were put forward to provide more innovative ideas for the further development of Chinese medicine industry. Text mining and statistical analysis methods were used to develop PMC index model for a quantitative evaluation of the content of 19 representative Chinese medicine industry policies. The results showed that 16 of the 19 policy portfolios were excellent policies,and 3 were good policies. Through the comparison of policies P16 and P2,P16 focused on the overall situation of the industry,while P2 focused more on the construction and development of Chinese medicine distribution bases,which was field-specific. It is recommended for good policies to refine financial support,talent training mechanisms and other measures to further strengthen policy guarantee.
作者
兰娅菲
韩朦
陈颖
褚淑贞
Lan Yafei(Research Center of National Drug Policy&Ecosystem,China Pharmaceutical University,Nanjing,P.R.China)
出处
《中国卫生事业管理》
北大核心
2022年第4期280-286,共7页
Chinese Health Service Management
基金
国家社会科学基金重大项目资助“我国创新药物政策环境研究”(15ZDB167)。
关键词
中医药产业
政策评价
PMC指数
traditional Chinese medicine industry
policy evaluation
PMC index
